Zobrazeno 1 - 10
of 335
pro vyhledávání: '"Elexacaftor/tezacaftor/ivacaftor"'
Autor:
Alice Castaldo, Paola Iacotucci, Sveva Bagnasco, Cristina Fevola, Vincenzo Carnovale, Fabio Antonelli, Gustavo Cernera, Monica Gelzo, Vito Terlizzi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Modulators of cystic fibrosis transmembrane conductance regulator (CFTR) improved cystic fibrosis (CF) patients’ outcome. The elexacaftor/tezacaftor/ivacaftor (ETI) combination was safe and effective improving lung function in patients wit
Externí odkaz:
https://doaj.org/article/03f3f0e21344435785561125f610e189
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-5 (2024)
Abstract Liver-related side effects are a known complication of treatment with elexacaftor/tezacaftor/ivacaftor (ETI) for cystic fibrosis (CF). Gilbert’s syndrome is caused by a genetic mutation that reduces activity of the enzyme UDP glucuronosylt
Externí odkaz:
https://doaj.org/article/e7f10fbf6acf4c76954ab790ee4ad480
Autor:
Michael P. Coughlin, Senthilkumar Sankararaman, Erica A. Roesch, Emily D. Certo, Benjamin L. Brej, Michael W. Konstan
Publikováno v:
Frontiers in Pediatrics, Vol 12 (2024)
This case report presents a comprehensive evaluation of the complex balance of therapeutic benefits and potential risks associated with the cystic fibrosis transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (ETI) th
Externí odkaz:
https://doaj.org/article/49b022be8573491d80a74a803d746159
Autor:
H.H. Jarosz-Griffiths, L.R. Caley, S. Lara-Reyna, S. Savic, I.J. Clifton, M.F. McDermott, D.G. Peckham
Publikováno v:
Heliyon, Vol 10, Iss 20, Pp e39244- (2024)
Background: Cystic fibrosis (CF) is associated with increased resting energy expenditure. However, the introduction of elexacaftor/tezacaftor/ivacaftor (ETI) has resulted in a paradigm shift in nutritional status for many people with CF, with increas
Externí odkaz:
https://doaj.org/article/7851ec2b76d0482ab485bfb3b4b1fd90
Autor:
Nela Stastna, Lenka Hrabovska, Pavel Homolka, Lukas Homola, Michal Svoboda, Kristian Brat, Libor Fila
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background Physical activity is a crucial demand on cystic fibrosis treatment management. The highest value of oxygen uptake (VO2peak) is an appropriate tool to evaluate the physical activity in these patients. However, there are several oth
Externí odkaz:
https://doaj.org/article/db6d0944aa9241948f90646ff0c462b0
Autor:
Harish Pudukodu, Margret Z. Powell, Agathe Ceppe, Scott H. Donaldson, Jennifer L. Goralski, Nathaniel A. Sowa
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 9, Pp n/a-n/a (2024)
ABSTRACT Objective Elexacaftor/tezacaftor/ivacaftor (E/T/I) has provided life‐changing pharmacotherapy for many people with cystic fibrosis (CF), but conflicting literature exists regarding the effect on mental health. While some reports suggest E/
Externí odkaz:
https://doaj.org/article/b8c0da60930648538af2d110c36c6b2f
Autor:
L. Gómez-Ganda, P. Galván-Blasco, A. Fernández-Polo, V. Cardona, B. García-Palop, CJ Parramón-Teixidó, E. Polverino, A. Álvarez-Fernández
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: Cystic fibrosis transmembrane conductance regulator modulators are the only available treatment for cystic fibrosis. Although elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is well-tolerated, rash has been reported as very frequent. In se
Externí odkaz:
https://doaj.org/article/0744480c2fbd4d819b6f3e8b0c837373
Publikováno v:
Heliyon, Vol 10, Iss 5, Pp e26955- (2024)
Cystic fibrosis (CF) is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Thousands of CFTR mutations have been identified, but only a fraction are known to cause CF, with the most common being the protot
Externí odkaz:
https://doaj.org/article/03d0aed7d3ac41279dab6883cec2584c
Autor:
Wolfgang Gruber, Florian Stehling, Christopher Blosch, Stefanie Dillenhoefer, Margarete Olivier, Folke Brinkmann, Cordula Koerner-Rettberg, Sivagurunathan Sutharsan, Uwe Mellies, Christian Taube, Matthias Welsner
Publikováno v:
Frontiers in Sports and Active Living, Vol 6 (2024)
BackgroundHabitual physical activity (PA) and exercise training are accepted as important aspects of care for people with cystic fibrosis (pwCF) to improve health-related measures of physical fitness, which in turn have a positive impact on quality o
Externí odkaz:
https://doaj.org/article/2e06f6f2ea37444f846398237506ca1b
Autor:
Alice Castaldo, Monica Gelzo, Paola Iacotucci, Annalisa Longobardi, Giovanni Taccetti, Vito Terlizzi, Vincenzo Carnovale
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2024)
Introduction: Modulators of cystic fibrosis transmembrane conductance regulator mutated protein significantly improved the outcome of patients with cystic fibrosis (CF). We describe 63 patients who were independently followed up in two CF regional ce
Externí odkaz:
https://doaj.org/article/d96ddba11e9b4871b12efa9b630f883e